AstraZeneca and its partner Ionis told the market their heart drug eplontersen, sold as Wainua, failed the study that mattered most. In the Phase 3 CARDIO-TTRansform trial, the drug did not beat placebo on the main goal: cutting the combined risk of cardiovascular death and repeat heart-related events over 140 weeks.
This was the expansion bet. Wainua is already approved for a nerve version of the same disease. The heart study was the door to a much larger group of patients, and it did not open.
AstraZeneca stock is trading near $173, down about 3% on the day and roughly 9% below where it sat before the news. Ionis is taking the harder hit, down more than 8% to around $59, because the heart indication was a bigger piece of its future than of AstraZeneca's.
The market they were chasing is already crowded
The disease is transthyretin amyloid cardiomyopathy, or ATTR-CM. A faulty protein builds up in the heart and stiffens it. Ten years ago there was no approved treatment. Today there are three, and they sell in volume.
Pfizer got there first with tafamidis, sold as Vyndaqel and Vyndamax. That franchise brought in $6.3 billion in 2025, up 17% from the year before, and added another $1.6 billion in the first quarter of 2026. Pfizer trades around $24 with a market value near $138 billion, and this heart franchise is one of the few reliable growth engines left in its lineup.
BridgeBio followed with acoramidis, sold as Attruby. It booked $362 million in its first full year and $180.6 million in the first quarter of 2026 alone. Analysts peg its share of new patients north of 25%. BridgeBio trades near $86, close to its 52-week high, with a market value around $17 billion. The company is not yet profitable, so the stock rides on how fast that ramp continues.
Alnylam rounds out the field with vutrisiran, sold as Amvuttra. It pulled in $889.9 million globally in the first quarter of 2026, up 187% year over year. Alnylam trades near $299 with a market value close to $40 billion, still well below its 52-week high above $495.
Why the failure is a bigger deal than it looks
Eplontersen and Alnylam's vutrisiran work the same basic way. Both lower the amount of the faulty protein the body makes. Vutrisiran ran a similar heart-outcomes study, hit its goal, and won approval. That is what made today's miss a surprise. The same mechanism that worked for one company did not clear the bar for another.
For the three incumbents, that removes a fourth competitor before it could arrive. Pfizer, BridgeBio, and Alnylam were fighting over pricing, oral-versus-injection convenience, and speed of diagnosis. They now do that without a deep-pocketed new entrant crowding the field.
The catch: the winners fell too
Here is the part that separates a headline from a trade. The three rivals did not rally on the news. BridgeBio is down about 4%, Alnylam is down about 4%, and Pfizer is roughly flat. On a day when a competitor just dropped out, that is telling.
Part of it is broad caution across biotech. Part of it is that a failed outcomes study, even a rival's, raises questions the whole category would rather avoid about how much these drugs change long-term survival. The structural read still favors the incumbents. The one-day tape says investors are not treating it as a simple gift.
AstraZeneca can absorb one miss
For AstraZeneca, this stings but does not break the story. The company did more than $60 billion in revenue last year, growing above 20%, and carries a pipeline deep enough that no single readout defines it. The stock trades around 17 times forward earnings with a dividend near 1.75%, below its own recent average and below the $224 analyst consensus target.
That gap is the setup. A large-cap drugmaker sells off on one failed study while the rest of the pipeline keeps moving. Whether that is a discount or a warning depends on the next several readouts, not this one.
What to watch from here
Watch whether BridgeBio and Alnylam recover the day's drop once the sector noise clears, since a durable bounce would confirm the market read that one less competitor is a net positive. Watch Pfizer's next quarterly update for whether tafamidis sales hold their double-digit growth against two oral rivals. And watch AstraZeneca's upcoming pipeline dates, because after a miss like this, the market wants proof the rest of the engine still runs.
